Compare ORN & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORN | PEPG |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.7M | 353.9M |
| IPO Year | 2007 | 2022 |
| Metric | ORN | PEPG |
|---|---|---|
| Price | $10.88 | $4.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $16.25 | $11.67 |
| AVG Volume (30 Days) | 424.4K | ★ 692.0K |
| Earning Date | 03-03-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | 25.61 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $852,260,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | $181.33 | ★ N/A |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $4.64 | $0.89 |
| 52 Week High | $15.00 | $7.80 |
| Indicator | ORN | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 36.81 |
| Support Level | $9.85 | $4.29 |
| Resistance Level | $11.70 | $5.50 |
| Average True Range (ATR) | 0.63 | 0.43 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 41.48 | 2.73 |
Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada, and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. The concrete segment generates maximum revenue and provides construction services for commercial, industrial, multi-family residential, and public projects, including the data center market.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.